Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BTB domain containing 9 (BTBD9) is a cytosolic protein encoded by the BTBD9 gene in humans and is characterized by the presence of a BTB/POZ domain, a protein-protein interaction module found in many eukaryotic proteins[1][3]. BTBD9 is highly expressed in the brain and various tissues and is implicated in multiple cellular processes, including cytoskeleton regulation, transcriptional regulation, ion channel assembly, vesicle recycling, and ubiquitination[1][2]. Its functions appear to include regulating synaptic plasticity, dopamine levels, and iron homeostasis. Genetic variations in BTBD9 are associated with increased risk for Restless legs syndrome and possibly Tourette syndrome but it is not established as a druggable therapeutic target, and there are currently no drugs or well-documented drug mechanisms acting directly on BTBD9[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BTB domain containing 9 (BTBD9).